Table 4.
Odds ratio for TDM measurement below and above the therapeutic target range for measured (actual) and harmonized sertraline concentration in different genotype-predicted CYP2C19 phenotype subgroups
| Genotype | Patients (n) | Sertraline levels <30 nM | Sertraline levels >250 nM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n | (%) | OR | (95% CI) | p | n | (%) | OR | (95% CI) | p | ||
| Measured concentration | |||||||||||
| UM | 351 | 99 | (28.2) | 1.31 | (0.95–1.80) | 0.098 | 20 | (5.7) | 0.84 | (0.46–1.47) | 0.541 |
| NM | 495 | 111 | (22.4) | — | — | — | 36 | (7.3) | — | — | — |
| IM | 321 | 54 | (16.8) | 0.67 | (0.46–0.96) | 0.032 | 39 | (12.1) | 1.97 | (1.21–3.21) | 0.064 |
| PM | 35 | 1 | (2.9) | 0.10 | (0.01–0.488) | 0.026 | 14 | (40.0) | 8.69 | (3.88–19.19) | <0.001 |
| Harmonized concentration | |||||||||||
| UM | 351 | 52 | (14.8) | 1.15 | (0.77–1.71) | 0.489 | 12 | (3.4) | 0.65 | (0.31–1.27) | 0.221 |
| NM | 495 | 65 | (13.1) | — | — | — | 36 | (5.3) | — | — | — |
| IM | 321 | 19 | (5.9) | 0.41 | (0.24–0.69) | 0.001 | 34 | (10.6) | 2.17 | (1.27–3.74) | 0.004 |
| PM | 35 | 0 | 0 | N/A | (N/A) | N/A | 17 | (48.6) | 17.8 | (8.09–39.16) | <0.001 |
N/A not applicable